about
Pyrazole-based cathepsin S inhibitors with arylalkynes as P1 binding elementsThioether acetamides as P3 binding elements for tetrahydropyrido-pyrazole cathepsin S inhibitorsDiazinones as P2 replacements for pyrazole-based cathepsin S inhibitorsOrganic cation transporter 3 modulates murine basophil functions by controlling intracellular histamine levelsA potent and selective histamine H4 receptor antagonist with anti-inflammatory propertiesIdentification of 2-arylbenzimidazoles as potent human histamine H4 receptor ligands.RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: a different interpretation of redundancy.Histamine H4-receptors inhibit mast cell renin release in ischemia/reperfusion via protein kinase C ε-dependent aldehyde dehydrogenase type-2 activationHistamine H4 receptor antagonism diminishes existing airway inflammation and dysfunction via modulation of Th2 cytokinesHistamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells.Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist.Inhibitory effects of histamine H4 receptor antagonists on experimental colitis in the rat.Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus.Cloning and pharmacological characterization of the dog histamine H4 receptor.Gene-Expression - Based Responses to Drug Treatment.Histamine H4 receptor optimizes T regulatory cell frequency and facilitates anti-inflammatory responses within the central nervous system.The histamine H4 receptor and potential therapeutic uses for H4 ligands.Cathepsin S inhibitors as novel immunomodulators.The mechanism of molecular redundancy in autoimmune inflammation in the context of CD44 deficiency.The histamine H4 receptor as a new therapeutic target for inflammation.The histamine H4 receptor in autoimmune disease.The histamine H(4) receptor: a novel modulator of inflammatory and immune disorders.Curvature, order, and dynamics of lipid hexagonal phases studied by deuterium NMR spectroscopy.Antagonism of the histamine H4 receptor reduces LPS-induced TNF production in vivo.The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines.TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders.The new biology of histamine receptors.Phosphoinositide 3-kinase gamma (PI3Kgamma) inhibitors for the treatment of inflammation and autoimmune disease.Recent advances in the design of cathepsin S inhibitors.The future antihistamines: histamine H3 and H4 receptor ligands.Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy.Antihistamines and itch.The histamine H4 receptor: from orphan to the clinic.Functional Profiling of 2-Aminopyrimidine Histamine H4 Receptor Modulators.Clinical Development of Histamine H4 Receptor Antagonists.The histamine H4 receptor is a potent inhibitor of adhesion-dependent degranulation in human neutrophils.The histamine H4 receptor mediates inflammation and Th17 responses in preclinical models of arthritisStructural requirements for inverse agonism and neutral antagonism of indole-, benzimidazole-, and thienopyrrole-derived histamine H4 receptor ligands.Discovery and SAR of novel pyrazole-based thioethers as cathepsin S inhibitors: part 1.Molecular determinants of ligand binding to H4R species variants.
P50
Q27657521-27B33C11-CDF4-4B76-862A-49294FBDCEC3Q27660062-AEC458B5-2914-470E-8E44-5DB98662FA34Q27662177-DE9E7ECE-31CD-42E0-808E-597B2A7921B6Q28510476-FB0577DC-B294-470C-BE84-9F85662B4BBEQ28571371-B9936308-E6E4-4DC8-A807-369322B86B24Q30823940-9D32932A-484A-4CF2-BED3-9D99D586AB12Q33582923-620D5AAC-20A0-4D1A-9E7C-5F8AB71D97FBQ33603610-1D207AAF-6988-4DED-A159-D20DC9F87387Q34039588-A446B4FD-8D18-4D73-BF51-38A3DA188434Q34182519-D76A6260-E536-480C-A699-E8F7E0683AF1Q34425247-90ED0B96-2E4F-4039-A69A-3797555B1B2EQ34458021-B7DF976B-846B-4274-BCFF-56C9536870F2Q34599024-9DC0D8AF-FB8F-46C8-8CA1-8DA562F213C2Q34798053-4A15123A-9E4B-4B47-8EFF-3C1732126145Q35099724-123ACF92-1FF2-40A1-975A-6B1481FFC9E0Q35658957-06E377B8-DCEF-453B-9EC1-7187C4184F8AQ35950458-A6B04AE3-629D-4FF7-8549-E4FB276648FCQ36137118-402A130D-81A7-4508-BD5E-7C995D75C634Q36193060-3953084C-ABB5-4D7B-8C3A-558F82EA9B41Q36212654-8BEF8AF6-FC7E-4FFD-9124-68A848C8DA6CQ36623087-988D8A24-E325-4BE3-B1D2-955557888967Q36726806-146DDCA9-5943-4C15-9F9C-44EA2F6E32CFQ36783621-31EBABD8-ABAF-4897-B31B-EDB7C0E3F483Q36844550-DB97A5AF-6C38-481B-912C-230023D94E9BQ37049023-0CB608BE-EEB0-4701-94C2-22B2AF01FBF3Q37066753-1191B30D-AAA5-445A-B28C-7E2233A2C4A1Q37123681-585F3526-3DBA-45CC-A3A0-F887CD468441Q37657564-D88B3BCB-839D-4421-9ACF-393263320AFAQ37718822-D9AA8107-D320-4570-BBE5-A7D07C0B2CFFQ37880829-6E8B2893-C0F3-44B1-BF96-33B84CE893C5Q38406862-926CD565-9843-4E7B-AFC5-9753BE139EB6Q38415140-9FDFCC3B-16A8-48AC-98DA-9D0DD6631525Q38421144-DC8BEA9E-EC55-4EA6-BFF9-233C2E3B2885Q38494116-E7B5C648-B46A-44C1-93CA-9A513F9A0DC0Q38944794-AB1D67AE-3031-4AC5-9A42-0B1B6B04B753Q38998092-02337BEB-B5B1-497B-B505-0BD7FF9E8896Q39332688-C8FA95DC-FF23-43BB-BF17-11CCBC5C5A7AQ39702424-5DC4EF26-46C1-45FF-AC9E-A4F6B32FDC61Q39739861-AD2D6E5E-FD1A-4045-BB62-73581F96167EQ39747626-0D4FDB52-9DF3-4607-AAF4-EBF099D64663
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Robin L Thurmond
@nl
Robin L Thurmond
@sl
Robin L. Thurmond
@en
Robin L. Thurmond
@es
type
label
Robin L Thurmond
@nl
Robin L Thurmond
@sl
Robin L. Thurmond
@en
Robin L. Thurmond
@es
altLabel
R L Thurmond
@en
R Thurmond
@en
R. L. Thurmond
@en
R. Thurmond
@en
Robin L Thurmond
@en
Robin Thurmond
@en
prefLabel
Robin L Thurmond
@nl
Robin L Thurmond
@sl
Robin L. Thurmond
@en
Robin L. Thurmond
@es
P214
P244
P106
P214
P244
n2010184062
P31
P496
0000-0001-6911-889X
P734
P735
P7859
lccn-n2010184062